ResMed Bundle
Who Owns ResMed?
ResMed, a pioneer in sleep and respiratory care, has transformed millions of lives with its innovative solutions. Understanding its ownership is key to grasping its market impact and strategic direction.
Founded in 1989, ResMed's journey began with a vision to improve respiratory health globally, particularly through technologies like CPAP machines. Today, it stands as a publicly traded company with a significant presence in the healthcare technology sector.
ResMed's ownership is diverse, primarily comprising institutional investors, public shareholders, and its founding members. As of August 2025, the company's market capitalization hovers around $41.7 billion to $41.88 billion. For fiscal year 2024, ResMed reported revenues of $4.685 billion, with projections for fiscal year 2025 reaching $5.146 billion. This financial strength reflects its broad ownership base and market confidence.
The company's governance and strategic decisions are influenced by its Board of Directors, who represent the interests of its shareholders. Key institutional holders, such as Vanguard Group Inc. and BlackRock Inc., hold substantial stakes, indicating significant investment from major financial entities. These institutions play a crucial role in ResMed's ongoing development and its ability to continue innovating in areas like sleep apnea treatment, as detailed in the ResMed PESTEL Analysis.
Who Founded ResMed?
ResMed was founded in June 1989 in Australia by Dr. Peter C. Farrell. His vision was to bring the nasal continuous positive airway pressure (CPAP) technology, initially developed by Professor Colin Sullivan and his team at the University of Sydney in 1981, to market. Dr. Farrell established ResMed to acquire the rights to this sleep apnea treatment from Baxter Healthcare.
| Founding Year | Founder | Initial Focus | Early Employee Count | Initial Revenue |
|---|---|---|---|---|
| 1989 | Dr. Peter C. Farrell | Commercializing CPAP technology | 9 | Less than $1 million (FY 1990) |
Pioneering Sleep Technology
ResMed's inception was driven by the commercialization of CPAP technology for obstructive sleep apnea (OSA). This technology was first developed at the University of Sydney.
Acquisition of Rights
Dr. Peter C. Farrell founded ResMed to acquire the sleep technology rights from Baxter Healthcare. Baxter had initially invested in the technology but decided not to enter the sleep apnea market.
Early Operations
In its first fiscal year, 1990, ResMed operated with a small team of nine employees. The company generated revenues below $1 million during this initial period.
Venture Capital Support
The company's early expansion and the acquisition of foundational sleep technology rights were supported by venture capital funding. Specific details on early angel investor or friends and family shareholdings are not publicly disclosed.
Leadership and Influence
Dr. Peter Farrell served as CEO from the company's inception, guiding its growth and global presence. He continued as Chairman until January 2023, demonstrating his significant and lasting impact on the company's strategy.
Market Entry
The establishment of ResMed marked a critical step in commercializing a treatment for obstructive sleep apnea. Understanding the Target Market of ResMed is key to appreciating its early business strategy.
The early ownership structure of ResMed was primarily shaped by the need to secure capital for technology acquisition and early-stage operations. While Dr. Peter C. Farrell was the founder and driving force, venture capital played a crucial role in enabling the company to acquire the necessary sleep technology rights and begin its growth trajectory. The company's initial financial performance, with revenues under $1 million in its first fiscal year, highlights the reliance on external investment during its formative stages.
Founding and Early Development
ResMed's journey began with a focus on a specific medical technology. The company's initial operations were lean, reflecting a typical startup phase.
- Founded in June 1989 by Dr. Peter C. Farrell.
- Commercialized nasal CPAP technology for obstructive sleep apnea (OSA).
- Technology originally developed by Professor Colin Sullivan's team.
- Acquired sleep technology rights from Baxter Healthcare.
ResMed SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has ResMed’s Ownership Changed Over Time?
ResMed's journey from its inception to becoming a publicly traded entity involved key milestones like its NASDAQ IPO in 1995 and subsequent NYSE listing in 1999. These events were crucial for securing capital to fuel its global expansion and innovation efforts.
| Shareholder Type | Percentage of Ownership (Approx.) | Key Holders (as of March 2025) |
|---|---|---|
| Institutional Investors | 63.02% - 64.40% | Vanguard Group Inc., BlackRock Inc., State Street Corp, Bank of New York Mellon Corp, Morgan Stanley, Geode Capital Management, LLC, Invesco Ltd. |
| Insider Ownership | 0.56% (as of June 2025) | Executives and Directors |
The current ResMed ownership structure is predominantly held by institutional investors, reflecting its status as a major public corporation. This broad ownership base means that control and strategic direction are typically influenced by these large investment firms and the company's board of directors, rather than a single dominant founder or private entity. Understanding who owns ResMed provides insight into its corporate governance and strategic priorities.
ResMed's Major Stakeholders
Institutional investors are the primary owners of ResMed, holding a substantial majority of its shares. This concentration of ownership among large financial institutions shapes the company's strategic direction and governance.
- Vanguard Group Inc. is a significant shareholder, holding approximately 12.63% of outstanding shares.
- BlackRock Inc. follows with a notable stake of around 8.67%.
- State Street Corp also maintains a considerable presence, owning about 4.48%.
- The overall institutional ownership stands between 63.02% and 64.40% as of August 2025.
- Insider ownership is minimal, at about 0.56% as of June 2025, indicating a dispersed ownership model.
The evolution of ResMed's ownership is a testament to its growth and integration into the global financial markets. For a deeper understanding of its historical trajectory, you can explore the Brief History of ResMed. This historical context is vital for comprehending the current ResMed stock ownership and how it influences the company's operations and future strategies.
ResMed PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on ResMed’s Board?
The Board of Directors at ResMed is instrumental in guiding the company's strategic direction and ensuring robust corporate governance. As of August 2024, the board comprises 11 members, including executive and independent directors, with Christopher DelOrefice being a recent addition. Michael 'Mick' Farrell, son of founder Dr. Peter C. Farrell, holds the positions of Chairman and Chief Executive Officer, continuing a legacy of family involvement in leadership.
| Director Name | Role | Key Committee Involvement |
|---|---|---|
| Michael 'Mick' Farrell | Chairman & CEO | |
| Karen Drexler | Director | |
| Jan De Witte | Director | |
| Desney Tan | Director | |
| Christopher DelOrefice | Director | Audit Committee |
ResMed operates under a standard one-share-one-vote system, meaning each share of common stock typically grants its holder one vote. This structure is common for publicly traded companies and ensures that voting power is directly proportional to share ownership. With insider ownership reported at approximately 0.56% as of June 2025, the influence of any single insider through voting power is limited. The company's proxy statements, such as the one issued in October 2024, provide detailed information on voting procedures for shareholders ahead of the annual meeting. There have been no significant proxy contests or activist campaigns reported that have substantially altered the company's decision-making processes in the past year, indicating a stable corporate structure.
Understanding ResMed's Ownership Structure
ResMed's corporate structure is designed to align shareholder interests with effective management. The company's voting power is distributed among its shareholders, with no single entity holding a dominant stake.
- ResMed follows a one-share-one-vote principle.
- Insider ownership is relatively low, around 0.56% as of June 2025.
- The Board of Directors oversees company strategy and governance.
- Michael 'Mick' Farrell, son of the founder, serves as Chairman and CEO.
- Shareholders receive voting instructions via proxy statements, such as the October 2024 issuance.
- Understanding Revenue Streams & Business Model of ResMed is key to appreciating its ownership dynamics.
ResMed Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped ResMed’s Ownership Landscape?
ResMed's ownership profile has been shaped by consistent financial growth and strategic capital allocation over the past few years. The company's commitment to shareholder returns, evidenced by increased dividends and share buybacks, continues to attract significant institutional investment, solidifying its ownership structure.
| Fiscal Year | Revenue | Gross Margin | Operating Profit |
| 2024 | $4.7 billion (+11%) | 56.7% (+90 bps) | N/A |
| Q3 FY2025 (ending March 31, 2025) | $1.3 billion (+8%) | N/A | +14% |
ResMed has demonstrated a strong financial performance, with an 11% revenue increase to $4.7 billion in fiscal year 2024 and a 90 basis point improvement in gross margin to 56.7%. For the third quarter of fiscal year 2025, revenue grew 8% year-over-year to $1.3 billion, exceeding expectations, and operating profit saw a 14% increase. The company's operating cash flow was robust at $579 million for the same quarter. ResMed has actively managed its capital through share repurchases, buying back $75.00 million in Q3 FY2025 and $69.85 million in Q4 FY2025, and repurchased 307,000 shares for $75 million in Q2 FY2025. The quarterly cash dividend has also been increased, reflecting confidence in future earnings. The acquisition of VirtuOx on April 30, 2025, highlights ongoing strategic investments. Leadership remains stable with Michael 'Mick' Farrell as Chairman and CEO. Institutional ownership remains high at 64.40% as of June 2025, underscoring the company's appeal to large investment funds. ResMed's strategic focus on demand generation, demand capture, and innovative health technology for out-of-hospital care is poised to drive future value for its stakeholders. Understanding the Growth Strategy of ResMed provides further insight into these trends.
Shareholder Returns
ResMed actively returns value to shareholders through share buybacks and increasing dividends. The company repurchased $75 million in shares in Q3 FY2025 and raised its quarterly dividend to $0.60 per share in July 2025.
Strategic Acquisitions
The company continues to invest strategically, with the recent acquisition of VirtuOx on April 30, 2025. This move reinforces its commitment to expanding its offerings in the health technology sector.
Institutional Ownership Dominance
Institutional investors hold a significant portion of ResMed's stock, with ownership at 64.40% as of June 2025. This high level of institutional backing indicates strong confidence from major investment entities.
Leadership and Future Outlook
Michael 'Mick' Farrell continues to lead as Chairman and CEO, providing stability. The company's focus on innovative health technologies for out-of-hospital care is expected to drive future growth.
ResMed Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of ResMed Company?
- What is Competitive Landscape of ResMed Company?
- What is Growth Strategy and Future Prospects of ResMed Company?
- How Does ResMed Company Work?
- What is Sales and Marketing Strategy of ResMed Company?
- What are Mission Vision & Core Values of ResMed Company?
- What is Customer Demographics and Target Market of ResMed Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.